New RNA drug ORN252 tested in humans for first time
NCT ID NCT07439796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new experimental drug called ORN252 in 20 healthy adults. ORN252 is a type of RNA therapy wrapped in a fat particle, designed to help the body make a protein that targets certain immune cells. The main goal is to check if it is safe and how the body handles it. This is a first step and does not aim to treat any disease yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORN252 (a lipid nanoparticle containing circular RNA that encodes a CAR protein targeting CD19)
What this could lead to
If safe, this could pave the way for future studies of ORN252 as a potential cancer therapy.
What could go wrong
This is a very early, small phase 1 trial in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it works against any disease. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
RECRUITINGHerston, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••